KhaledATolbaMD

PubMed

• Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
  Jeff Yorio, Katherine T Lofgren, Jessica K Lee, Khaled Tolba, Geoffrey R Oxnard, Alexa B Schrock, Richard S P Huang, Lorraine Brisbin> ;JCO Precision Oncology. 2024 Mar 1
• Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
  Mack, P., Keller-Evans, R., Li, G., Lofgren, K., Schrock, A., Trabucco, S., Allen, J., Huang, R., Tolba, K., Oxnard, G.> ;The Oncologist. 2024 Feb 24
• 11 citations
  Genomic landscape of 891 RET fusions detected across diverse solid tumor types.
  Vamsi Parimi, Khaled Tolba, Natalie Danziger, Zheng Kuang, Daokun Sun, Douglas I Lin, Matthew C Hiemenz, Alexa B Schrock, Jeffrey S Ross, Geoffrey R Oxnard, Richard S ...> ;NPJ Precision Oncology. 2023 Jan 23
• 9 citations
  Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
  Richard S P Huang, David P Carbone, Gerald Li, Alexa Schrock, Ryon P Graf, Liangliang Zhang, Karthikeyan Murugesan, Jeffrey S Ross, Khaled Tolba, Jacob Sands, Geoffrey...> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
• 5 citations
  Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma.
  Bharathi Muthusamy, Kira Raskina, Katherine T Lofgren, Gerald Li, Khaled Tolba, Karen Schwed, Emily Castellanos, Richard S P Huang, Geoffrey R Oxnard, Alexa B Schrock,...> ;Journal of Thoracic Oncology. 2023 Apr 1
• 7 citations
  Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
  Richard S P Huang, Lukas Harries, Brennan Decker, Matthew C Hiemenz, Karthikeyan Murugesan, James Creeden, Khaled Tolba, Laura P Stabile, Shakti H Ramkissoon, Timothy ...> ;The Oncologist. 2022 Oct 1
• 12 citations
  Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
  Lee S Schwartzberg, Gerald Li, Khaled Tolba, Ariel B Bourla, Katja Schulze, Rujuta Gadgil, Alexander Fine, Katherine T Lofgren, Ryon P Graf, Geoffrey R Oxnard, Davey D...> ;JTO Clinical and Research Reports. 2022 Sep 1
• 7 citations
  Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy.
  Ericka M Ebot, Daniel L Duncan, Khaled Tolba, David Fabrizio, Garrett M Frampton, Leah A Comment, Lee A Albacker> ;NPJ Precision Oncology. 2022 Jun 23
• 28 citations
  Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
  Jacques Cadranel, Stephen V. Liu, Michael Duruisseaux, Eva Brandén, Yasushi Goto, Benjamin A. Weinberg, Christoph Heining, Richard F. Schlenk, Parneet Cheema, Martin R...> ;The Oncologist. 2021 Jan 1
• 22 citations
  Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
  Ole Gjoerup, Charlotte Brown, Jeffrey S. Ross, Richard S.P. Huang, Alexa B. Schrock, James Creeden, David Fabrizio, K. Tolba> ;The AAPS Journal. 2020 Oct 14
• 62 citations
  NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
  Janessa Laskin, Stephen V. Liu, Khaled A. Tolba, Christoph Heining, Richard F. Schlenk, Parneet Cheema, Jacques Cadranel, M.R. Jones, A. Drilon, Agnieszka Cseh, S. Gyo...> ;Annals of Oncology. 2020 Dec 1
• 51 citations
  Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
  Ying Wang, Carol Beadling, Andrea Warrick, Tanaya Neff, Christopher L. Corless, Khaled A. Tolba> ;Journal of Thoracic Oncology. 2017 Aug 1
• 40 citations
  Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer:...
  Harold J. Wanebo, Ju-Whei Lee, Barbara Burtness, John A. Ridge, Musie Ghebremichael, Sharon A. Spencer, D. Psyrri, Eirini Pectasides, David L. Rimm, F. R. Rosen, M. R....> ;Annals of Oncology. 2014 Oct 1
• 5 citations
  Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Car...
  Kunal Saigal, Edgardo S. Santos, Khaled A. Tolba, Deukwoo Kwon, Nagy Elsayyad, Matthew C. Abramowitz, Amar Mandalia, Michael A. Samuels> ;Frontiers in Oncology. 2014 Jun 30
• 325 citations
  A phase I dose-escalation trial of 2-deoxy- d -glucose alone or combined with docetaxel in patients with advanced solid tumors
  Luis E. Raez, Kyriakos P. Papadopoulos, A. Ricart, E. Gabriella Chiorean, Robert S. DiPaola, Mark N. Stein, Caio Max S. Rocha Lima, James J. Schlesselman, Khaled A. To...> ;Cancer Chemotherapy and Pharmacology. 2013 Feb 1
• 14 citations
  Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
  Bruno R. Bastos, Georges Hatoum, Gail Walker, Khaled A. Tolba, Christiane Takita, Jorge Gomez, Edgardo S. Santos, Gilberto Lopes, Luis E. Raez> ;Journal of Thoracic Oncology. 2010 Apr 1
• 17 citations
  Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response
  Hyun Mi Cho, Joseph D. Rosenblatt, Khaled A. Tolba, Sarah J. Shin, Daniel Sanghoon Shin, Carmen Calfa, Yu Zhang, Seung Uon Shin> ;Cancer Research. 2009 Dec 15
• 111 citations
  HSV ICP0 recruits USP7 to modulate TLR-mediated innate response
  Sandrine Daubeuf, Divyendu Singh, Yaohong Tan, Hongiu Liu, Howard J. Federoff, William J. Bowers, Khaled A. Tolba> ;Blood. 2009 Apr 2
• Radiaton pneumonitis with the combination of irinotecan and carboplatin concomitantly with radiation for stage III non-small cell lung cancer.
  Raez LE, Hatoum G, Bastos BR, Walker G, Tolba K, Farfan N, Karr M, Kobina S, Rodriguez V, Rocha-Lima CM> ;J. Clin. Oncol.. 2008-05-20
• 4 citations
  Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction
  Hovav Nechushtan, Dien Pham, Yu Zhang, Daniel Morgensztern, Kyung H. Yi, Seung Uon Shin, Howard J. Federoff, William J. Bowers, Khaled A. Tolba, Joseph D. Rosenblatt> ;Cancer Immunology, Immunotherapy. 2008 May 1
• 16 citations
  Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity I...
  Kyung H. Yi, Hovav Nechushtan, William J. Bowers, Gail Walker, Yu Zhang, Dien G. Pham, Eckhard R. Podack, Howard J. Federoff, Khaled A. Tolba, Joseph D. Rosenblatt> ;Cancer Research. 2007 Oct 15
• 8 citations
  Modulation of dendritic cell differentiation and function by YopJ of Yersinia pestis
  Inna Lindner, Julie Torrvellas-Garcia, Despina Kolonias, Louise M. Carlson, Khaled A. Tolba, Gregory V. Plano, Kelvin P. Lee> ;European Journal of Immunology. 2007 Sep 1
• Efficacy and safety profile of oxaliplatin and docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
  Santos ES, Raez LE, Rosado M, Lopes G, Roman E, Kumar P, Tolba K, Silva O, Rocha-Lima C, Hamilton K> ;J. Clin. Oncol.. 2006-06-20
• Oxaliplatin and docetaxel as first line chemotherapy for patients with non-small cell lung cancer (NSCLC).
  Santos ES, Raez LE, Rocha-Lima C, Tolba K, Negret L, Farfan N, Decesare T, Lopes G, Rosado MF, Wu J> ;J. Clin. Oncol.. 2005-06-01
• HSV amplicon mediated augmentation of antitumor effects induced by tumor-specific T cells in the lymphopenic host.
  Morgensztern D, Rosenblatt JD, Pham DG, Yi K, Shah S, Tolba KA, Nechushtan H> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all

Books/Book Chapters

• Rubin's Clinical Oncology 
  Chapter: Cancer Gene Therapy 
  Tolba K, Federoff HJ, Rosenblatt JDEdition 8th,1998